Non-inferiority Study in Patients With Complete Pathological Response After Neoadjuvant Chemotherapy and Negative VABB Biopsy Undergoing RT Alone, Omitting Surgical Treatment
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 77
- 试验地点
- 4
- 主要终点
- Event-free survival
研究概览
简要总结
This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant chemotherapy (NACT). The study design involves the histological confirmation of pCR using vacuum-assisted biopsy (VABB) or vacuum-assisted excision (VAE) guided by ultrasound. The primary objective is to demonstrate that the non-surgical, RT-only treatment and follow-up approach is not inferior to the traditional surgical approach in patients with pCR after NACT.
详细描述
Neoadjuvant chemotherapy (NACT) in breast cancer is considered the "gold standard" for the treatment of locally advanced and inoperable malignancies.
In recent years, in view of the evidence gathered, it has also become a conventional treatment alternative for patients with operable disease who are possible candidates for adjuvant chemotherapy. NACT thus aims to reduce mortality and increase surgical options, while at the same time allowing in vivo chemosensitivity testing. In view of this, NACT represents the ideal setting for clinical and translational research, which nowadays also has to address the question of future treatment options.
It is indeed a source of lively debate whether chemotherapy should be considered the only possible treatment option for the patient.
This study falls into this context, the innovative aim of which is to demonstrate histologically with the use of VABB, the complete pathological response (pCR) and to avoid surgery.
The main aim of this study is to show that a non-surgical, radiotherapy-only treatment and follow-up approach is not inferior to a surgical approach for patients who have shown complete pathological response (pCR) following neoadjuvant chemotherapy (NACT), as confirmed through histological analysis of imaging-guided sampling.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age> 18 years
- •infiltrating breast carcinoma, non-special histotype, triple negative or HER2 +, T1-T2 N0
- •single lesion
- •neo-adjuvant chemotherapy treatment for at least 12 weeks according to clinical practice
- •conservative surgery proposal
- •tumour bed identified by breast markers placed in pre NACT by radiologist
排除标准
- •Bilateral or multicentric tumour
- •Presence of microcalcifications visualised on mammography
- •Presence of associated DCIS
- •Positive history of previous breast cancer
- •Positive history of medical or psychiatric conditions preventing adherence to the protocol
- •High risk patient
结局指标
主要结局
Event-free survival
时间窗: 5 years
Absence of disease recurrence or progression, second primary tumor, or death
次要结局
- Contrast-Enhanced Mammography (CEM) positive predictive value(6 months)
- Positive predictive value of MRI(6 months)
